Physician profile
Brian Lee
NPI 1447679212
$10,087.93
in general payments reported to CMS, 2019-2025
24 companies · $2,382 in 2025
The $2,382 reported for 2025 was more than what 81% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $349 · 2021: $735 · 2022: $1,435 · 2023: $2,153 · 2024: $2,857 · 2025: $2,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,366 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,366.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,807.91 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Abbott Laboratories | $559.88 | 2019-2024 | Eterna |
| Globus Medical, INC. | $478.87 | 2024-2025 | Senza, Sable, Monument |
| Boston Scientific Corporation | $464.26 | 2019-2025 | Infinion 16, Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $414.55 | 2020-2025 | Belbuca, Xtampza |
| Nevro Corp. | $185.35 | 2021-2024 | Senza |
| Grt US Holding, INC. | $174.21 | 2021-2022 | |
| Biotronik Nro, INC. | $135.39 | 2023 | Biotronik |
| Stimwave Technologies Incorporated | $129.80 | 2022 | |
| Medtronic USA, INC. | $127.80 | 2020 | |
| Curonix LLC | $103.14 | 2022-2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Vertex Pharmaceuticals Incorporated | $82.62 | 2025 | |
| Averitas Pharma INC. | $77.84 | 2023-2025 | Qutenza |
| Gilead Sciences, INC. | $68.47 | 2019-2021 | |
| Depuy Synthes Sales INC. | $51.50 | 2024 | Monovisc, Orthovisc, Peak |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $42.47 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.39 | 2023-2025 | Relistor |
| Pacira Therapeutics, INC. | $29.76 | 2020 | |
| Becton, Dickinson and Company | $25.00 | 2024 | |
| Tersera Therapeutics LLC | $23.98 | 2021 | |
| Spr Therapeutics, INC | $21.96 | 2025 | Sprint Pns System |
| Horizon Therapeutics Plc | $21.73 | 2021 | |
| Electronic Waveform Lab, INC. | $15.21 | 2025 | |
| Allergan, INC. | $13.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.